natgillin/translations-raw huggingface dataset:
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Hranilo, snov, živilo ali kategorija živil
Fabenol® Max reduces the absorption of carbohydrates
Trditev
Polydextrose
Zdravstvena trditev po členu 13(5), ki je utemeljena na novih znanstvenih dokazih in/ali vključuje zahtevo za zakonsko zaščito podatkov
Polydextrose contributes to an improved bowel function by increasing stool bulk
Fabenol® Max zmanjšuje absorpcijo ogljikovih hidratov.
Pursuant to Regulation (EC) No 1924/2006 health claims made on foodsare prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims.
V skladu z Uredbo (ES) št. 1924/2006 so zdravstvene trditve na živilih prepovedane, razen če jih Komisija v skladu z navedeno uredbo odobri in uvrsti na seznam dovoljenih trditev.
Following an application from Beghin-Meiji and Tereos Syral, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to short-chain fructooligosaccharides from sucrose and maintenance of normal defecation (Question No EFSA-Q-2015-00377 [2]).
Družba Beghin-Meiji in Tereos Syral je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi s kratkoverižnimi fruktooligosaharidi iz saharoze in vzdrževanjem normalne defekacije (vprašanje št.
The applicant has proposed the following wording for the health claim: ‘maintain normal intestinal regularity’ or ‘maintain intestinal regularity by increasing the frequency of bowel movements’ or ‘contributes to normal intestinal regularity or normal bowel function’.
EFSA-Q-2015-00377 [2]).
On 8 January 2016, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of short-chain fructooligosaccharides from sucrose and maintenance of normal defecation under the conditions of use proposed by the applicant.
Vložnik je predlagal naslednjo zdravstveno trditev: „Vzdržujejo normalno in redno črevesno delovanje.“ ali „Vzdržujejo redno črevesno delovanje, tako da povečujejo pogostost odvajanja blata.“ ali „Prispevajo k normalnemu in rednemu črevesnemu delovanju ali normalnemu delovanju črevesja.“
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Komisija in države članice so 8. januarja 2016 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem kratkoverižnih fruktooligosaharidov iz saharoze in vzdrževanjem normalne defekacije pod pogoji uporabe, ki jih je predlagal vložnik, ni utemeljena.
The comments from the applicant received by the Commission pursuant to Article 16(6) of Regulation (EC) No 1924/2006 have been considered when setting the measures provided for in this Regulation.
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,
Pri določanju ukrepov iz te uredbe so bile upoštevane pripombe, ki jih je vložnik poslal Komisiji v skladu s členom 16(6) Uredbe (ES) št. 1924/2006.
The health claim listed in the Annex to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.
Člen 1
Article 2
Zdravstvena trditev iz Priloge k tej uredbi se ne uvrsti na seznam dovoljenih trditev Unije v skladu s členom 13(3) Uredbe (ES) št. 1924/2006.
Done at Brussels, 5 July 2017.
Ta uredba je v celoti zavezujoča in se neposredno uporablja v vseh državah članicah.
For the Commission
V Bruslju, 5. julija 2017
Short-chain fructooligosaccharides from sucrose
Kratkoverižni fruktooligosaharidi iz saharoze
Maintain normal intestinal regularity
Vzdržujejo normalno in redno črevesno delovanje.
Following an application from Granarolo S.p.A., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to a low-fat fermented milk with a combination of fructooligosaccharides and live Lactobacillus rhamnosus GG (ATCC 53103), Streptococcus thermophilus (Z57) and Lactobacillus delbrueckii subsp. bulgaricus (LB2), and defence against reactivation of Herpes simplex virus in the orolabial epithelia (Question No EFSA-Q-2015-00488 [2]).
Družba Granarolo S.p.A. je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z nizkomaščobnim fermentiranim mlekom skupaj s fruktooligosaharidi in živimi bakterijami Lactobacillus rhamnosus GG (ATCC 53103), Streptococcus thermophilus (Z57) in Lactobacillus delbrueckii subsp. bulgaricus (LB2) ter zaščito pred reaktivacijo virusa herpes simpleks na orolabialnem epitelu (vprašanje št.
The claim proposed by the applicant was worded as follows: ‘Consumption of low-fat fermented milk with a combination of fructo-oligosaccharides (FOS) and live Lactobacillus rhamnosus GG (ATCC 53103), Streptococcus thermophilus (Z57) and Lactobacillus delbrueckii subsp. bulgaricus (LB2) helps to reduce recurrence of lip cold sores caused by Herpes simplex virus infection in healthy susceptible individuals’.
EFSA-Q-2015-00488 [2]).
On 19 July 2016, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of the low-fat fermented milk, which was the subject of the health claim, and defence against reactivation of Herpes simplex virus in the orolabial epithelia.
Vložnik je predlagal naslednjo trditev: „Uživanje nizkomaščobnega fermentiranega mleka skupaj s fruktooligosaharidi (FOS) in živimi bakterijami Lactobacillus rhamnosus GG (ATCC 53103), Streptococcus thermophilus (Z57) in Lactobacillus delbrueckii subsp. bulgaricus (LB2) pomaga zmanjševati ponavljanje ran na ustnici, ki jih povzroča okužba z virusom herpes simpleks pri zdravih dovzetnih osebah.“
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Komisija in države članice so 19. julija 2016 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem nizkomaščobnega fermentiranega mleka, ki je bilo zadeva zdravstvene trditve, in zaščito pred reaktivacijo virusa herpes simpleks na orolabialnem epitelu ni utemeljena.
Following an application from Food for Health Ireland, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to FHI LFC24, a bovine milk-derived casein hydrolysate, and a reduction of post-prandial blood glucose responses (Question No EFSA- Q-2015-00755 [3]).
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
The claim proposed by the applicant was worded as follows: ‘FHI LFC24 helps to regulate blood glucose levels following food consumption’.
Družba Food for Health Ireland je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z izdelkom FHI LFC24, kazeinskim hidrolizatom iz mleka goveda, in zmanjšanjem postprandialnega glikemičnega odziva (vprašanje št.
On 22 July 2016, the Commission and the Member States received the scientific opinion from the Authority, which noted that the evidence provided by the applicant does not establish that a reduction in post-prandial glycaemic responses achieved by an increase in insulin secretion is a beneficial physiological effect for the target population of the claim.
EFSA-Q-2015-00755 [3]).
Therefore, on the basis of the data presented, the Authority concluded that a cause and effect relationship had not been established between the consumption of the food subject to the claim and a beneficial physiological effect for the target population.
Vložnik je predlagal naslednjo trditev: „FHI LFC24 pomaga uravnavati raven glukoze v krvi po uživanju hrane.“
Following an application from Pierre Fabre Medicament, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to V0137, a ‘DHA-enriched fish oil’, and ‘helps to slow the age-related cognitive decline in domains such as memory and executive function’ (Question No EFSA- Q- 2016-00071 [4]).
Komisija in države članice so 22. julija 2016 prejele znanstveno mnenje Agencije, v katerem je navedeno, da dokazi, ki jih je predložil vložnik, ne dokazujejo, da je zmanjšanje postprandialnega glikemičnega odziva, ki se doseže s povečanjem izločanja inzulina, pozitiven fiziološki učinek za ciljno populacijo.
The claim proposed by the applicant was worded as follows: ‘V0137, in association with physical and intellectual training, helps to slow the age-related cognitive decline in domains such as memory and executive function’.
Agencija je tako na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem izdelka, ki je zadeva zdravstvene trditve, in pozitivnim fiziološkim učinkom za ciljno populacijo ni utemeljena.
On 5 August 2016, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of V0137, which was the subject of the health claim, and a reduced loss of cognitive function.
Družba Pierre Fabre Medicament je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z izdelkom V0137, „ribjim oljem, obogatenim z dokozaheksaenojsko kislino“, in „pomaga upočasnjevati s starostjo povezan upad kognitivnih sposobnosti na področjih, kot so spomin in izvršilne funkcije“ (vprašanje št.
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,
EFSA-Q-2016-00071 [4]).
HAS ADOPTED THIS REGULATION:
Vložnik je predlagal naslednjo trditev: „V0137 skupaj s fizičnimi in intelektualnimi vajami pomaga upočasnjevati s starostjo povezan upad kognitivnih sposobnosti na področjih, kot so spomin in izvršilne funkcije.“
Article 1
Komisija in države članice so 5. avgusta 2016 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem izdelka V0137, ki je bil zadeva zdravstvene trditve, in zmanjšano izgubo kognitivnih funkcij ni utemeljena.
Done at Brussels, 5 July 2017.
Člen 2
OJ L 404, 30.12.2006, p. 9.
V Bruslju, 5. julija 2017
EFSA Journal 2016;14(7):4538
Za Komisijo
EFSA Journal 2016;14(7):4540
Predsednik
EFSA Journal 2016;14(8):4539
UL L 404, 30.12.2006, str. 9.
EFSA opinion reference
Vloga – ustrezne določbe Uredbe (ES) št. 1924/2006
Low-fat fermented milk with a combination of fructo-oligosaccharides (FOS) and live Lactobacillus rhamnosus GG (ATCC 53103), Streptococcus thermophilus (Z57) and Lactobacillus delbrueckii subsp. bulgaricus (LB2).
Trditev
Consumption of low-fat fermented milk with a combination of fructo-oligosaccharides (FOS) and live Lactobacillus rhamnosus GG (ATCC 53103), Streptococcus thermophilus (Z57) and Lactobacillus delbrueckii subsp. bulgaricus (LB2) helps to reduce recurrence of lip cold sores caused by Herpes simplex virus infection in healthy susceptible individuals.
Referenčno mnenje Evropske agencije za varnost hrane
FHI LFC24, a bovine milk-derived casein hydrolysate.
Zdravstvena trditev po členu 13(5), ki je utemeljena na novih znanstvenih dokazih in/ali vključuje zahtevo za zakonsko zaščito podatkov
FHI LFC24 helps to regulate blood glucose levels following food consumption.
Nizkomaščobno fermentirano mleko skupaj s fruktooligosaharidi (FOS) in živimi bakterijami Lactobacillus rhamnosus GG (ATCC 53103), Streptococcus thermophilus (Z57) in Lactobacillus delbrueckii subsp. bulgaricus (LB2).
V0137, a DHA enriched fish oil.
Uživanje nizkomaščobnega fermentiranega mleka skupaj s fruktooligosaharidi (FOS) in živimi bakterijami Lactobacillus rhamnosus GG (ATCC 53103), Streptococcus thermophilus (Z57) in Lactobacillus delbrueckii subsp. bulgaricus (LB2) pomaga zmanjševati ponavljanje ran na ustnici, ki jih povzroča okužba z virusom herpes simpleks pri zdravih dovzetnih osebah.
V0137, in association with physical and intellectual training, helps to slow the age-related cognitive decline in domains such as memory and executive function.
FHI LFC24, kazeinski hidrolizat iz mleka goveda.
amending Directive 2002/46/EC of the European Parliament and of the Council and Regulation (EC) No 1925/2006 of the European Parliament and of the Council as regards organic silicon (monomethylsilanetriol) and calcium phosphoryl oligosaccharides (POs-Ca®) added to foods and used in the manufacture of food supplements
o spremembi Direktive 2002/46/ES Evropskega parlamenta in Sveta ter Uredbe (ES) št. 1925/2006 Evropskega parlamenta in Sveta v zvezi z organskim silicijem (monometilsilanetriolom) in kalcijevimi fosforil oligosaharidi (POs-Ca®), dodanimi živilom in uporabljenimi pri proizvodnji prehranskih dopolnil
Having regard to Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins and minerals and of certain other substances to foods [2], and in particular Article 3(3) thereof,
ob upoštevanju Uredbe (ES) št. 1925/2006 Evropskega parlamenta in Sveta z dne 20. decembra 2006 o dodajanju vitaminov, mineralov in nekaterih drugih snovi živilom [2] ter zlasti člena 3(3) Uredbe,
Annex II to Directive 2002/46/EC establishes the list of vitamin and mineral substances, which may be used in the manufacture of food supplements.
Priloga II k Direktivi 2002/46/ES določa seznam vitaminskih in mineralnih snovi, ki se lahko uporabljajo pri proizvodnji prehranskih dopolnil.
According to Article 14 of Directive 2002/46/EC, provisions on vitamin and mineral substances in food supplements which may have an effect upon public health are to be adopted after consultation with the European Food Safety Authority (‘the Authority’).
V skladu s členom 14 Direktive 2002/46/ES je treba predpise o vitaminih in mineralih v prehranskih dopolnilih, ki lahko vplivajo na javno zdravje, sprejeti po posvetovanju z Evropsko agencijo za varnost hrane (v nadaljnjem besedilu: Agencija).
Annex II to Regulation (EC) No 1925/2006 establishes the list of vitamin and mineral substances, and for each of them the forms, which may be added to foods.
V Prilogi II k Uredbi (ES) št. 1925/2006 je določen seznam vitaminov in mineralov ter njihove oblike, ki se lahko dodajo živilom.
According to Article 3(3) of Regulation (EC) No 1925/2006, modifications to the list provided in Annex II to that Regulation are to be adopted taking account of the opinion of the Authority.
V skladu s členom 3(3) Uredbe (ES) št. 1925/2006 je treba spremembe seznama iz Priloge II k navedeni uredbi sprejeti ob upoštevanju mnenja Agencije.
Following a request for the addition of organic silicon as a source of silicon to the list set out in Annex II to Directive 2002/46/EC, on 9 March 2016 the Authority adopted a Scientific Opinion on the safety of organic silicon (monomethylsilanetriol; MMST) as a novel food ingredient for use as a source of silicon in food supplements and bioavailability of orthosilicic acid from the source [3].
Po zahtevku za vključitev organskega silicija kot vira silicija na seznam iz Priloge II k Direktivi 2002/46/ES je Agencija 9. marca 2016 sprejela znanstveno mnenje o varnosti organskega silicija (monometilsilanetriola; MMST) kot nove živilske sestavine za uporabo kot vira silicija v prehranskih dopolnilih in o biološki razpoložljivosti ortosilicijeve kisline iz vira [3].
It follows from that opinion that the use of organic silicon (monomethylsilanetriol) in food supplements is not of a safety concern as a source of silicon, provided that certain conditions are respected.
Iz navedenega mnenja sledi, da je uporaba organskega silicija (monometilsilanetriola) kot vira silicija v prehranskih dopolnilih varna, če so izpolnjeni določeni pogoji.
Taking into account the Authority's favourable opinion, organic silicon (monomethylsilanetriol) should be included in the list set out in Annex II to Directive 2002/46/EC.
Ob upoštevanju ugodnega mnenja Agencije bi bilo treba organski silicij (monometilsilanetriol) vključiti na seznam iz Priloge II k Direktivi 2002/46/ES.
Following a request for the addition of calcium phosphoryl oligosaccharides (POs-Ca®) as a source of calcium to the list set out in Annex II to Directive 2002/46/EC and to the list set out in Annex II to Regulation (EC) No 1925/2006, on 26 April 2016 the Authority adopted a Scientific Opinion on the safety of calcium phosphoryl oligosaccharides (POs-Ca®) as a source of calcium added for nutritional purposes to food, food supplements and foods for special medical purposes [4].
Po zahtevku za vključitev kalcijevih fosforil oligosaharidov (POs-Ca®) kot vira kalcija na seznam iz Priloge II k Direktivi 2002/46/ES in na seznam iz Priloge II k Uredbi (ES) št. 1925/2006 je Agencija 26. aprila 2016 sprejela znanstveno mnenje o varnosti kalcijevih fosforil oligosaharidov (POs-Ca®) kot vira kalcija, dodanega za prehranske namene v živila, prehranska dopolnila in živila za posebne zdravstvene namene [4].
It follows from that opinion that the addition of calcium phosphoryl oligosaccharides (POs-Ca®) to food and its use in food supplements is not of a safety concern as a source of calcium, provided that certain conditions are respected.
Iz navedenega mnenja sledi, da sta dodajanje kalcijevih fosforil oligosaharidov (POs-Ca®) v živila in njihova uporaba v prehranskih dopolnilih kot vira kalcija varna, če so izpolnjeni določeni pogoji.
Taking into account the Authority's favourable opinion, calcium phosphoryl oligosaccharides (POs-Ca®) should be included in the list set out in Annex II to Directive 2002/46/EC and in the list set out in Annex II to Regulation (EC) No 1925/2006.
Ob upoštevanju ugodnega mnenja Agencije bi bilo treba kalcijeve fosforil oligosaharide (POs-Ca®) vključiti na seznam iz Priloge II k Direktivi 2002/46/ES in na seznam iz Priloge II k Uredbi (ES) št. 1925/2006.
Directive 2002/46/EC and Regulation (EC) No 1925/2006 should therefore be amended accordingly.
Direktivo 2002/46/ES in Uredbo (ES) št. 1925/2006 bi zato bilo treba ustrezno spremeniti.
Annex II to Directive 2002/46/EC is amended in accordance with the Annex to this Regulation.
Priloga II k Direktivi 2002/46/ES se spremeni v skladu s Prilogo k tej uredbi.
Annex II to Regulation (EC) No 1925/2006 is amended in accordance with the Annex to this Regulation.
Priloga II k Uredbi (ES) št. 1925/2006 se spremeni v skladu s Prilogo k tej uredbi.
Done at Brussels, 5 July 2017.
V Bruslju, 5. julija 2017
OJ L 183, 12.7.2002, p. 51.
UL L 183, 12.7.2002, str. 51.
OJ L 404, 30.12.2006, p. 26.
UL L 404, 30.12.2006, str. 26.
EFSA Journal 2016;14(4):4436
EFSA Journal 2016;14(4):4436.
EFSA Journal 2016;14(6):4488
EFSA Journal 2016;14(6):4488.
Point B of Annex II to Directive 2002/46/EC is amended as follows:
Točka B Priloge II k Direktivi 2002/46/ES se spremeni:
the following entry is inserted after the entry for ‘silicic acid’:
Za vnosom za „silicijevo kislino“ se vstavi naslednji vnos:
‘organic silicon (monomethylsilanetriol)’;
„organski silicij (monometilsilanetriol)“;
the following entry is inserted after the entry ‘calcium sulphate’:
Za vnosom za „kalcijev sulfat“ se vstavi naslednji vnos:
‘calcium phosphoryl oligosaccharides’.
„kalcijevi fosforil oligosaharidi“.
In point 2 of Annex II to Regulation (EC) No 1925/2006 the following entry is inserted after the entry ‘calcium sulphate’:
V točki 2 Priloge II k Uredbi (ES) št. 1925/2006 se za vnosom za „kalcijev sulfat“ vstavi naslednji vnos:
Commission Implementing Regulation (EU) 2017/1204
Izvedbena uredba Komisije (EU) 2017/1204
correcting the Slovak language version of Implementing Regulation (EU) 2015/2403 establishing common guidelines on deactivation standards and techniques for ensuring that deactivated firearms are rendered irreversibly inoperable
o popravku slovaške jezikovne različice Izvedbene uredbe (EU) 2015/2403 o določitvi skupnih smernic o standardih in tehnikah za onesposobitev, ki zagotavljajo nepreklicno neuporabnost onesposobljenega strelnega orožja
Having regard to Council Directive 91/477/EEC of 18 June 1991 on control of the acquisition and possession of weapons [1], and in particular the second paragraph of Part III of Annex I thereto,
ob upoštevanju Direktive Sveta 91/477/EGS z dne 18. junija 1991 o nadzoru nabave in posedovanja orožja [1] ter zlasti drugega odstavka dela III Priloge I k Direktivi,
The Slovak language version of Commission Implementing Regulation (EU) 2015/2403 [2] contains an error in Article 1(2), whereby the word ‘unless’ was erroneously translated as ‘if’, thus conveying the contrary of the intended meaning.
Slovaška jezikovna različica Izvedbene uredbe Komisije (EU) 2015/2403 [2] vsebuje napako v členu 1(2), saj je bila angleška beseda „razen če“ napačno prevedena s slovaško besedo, ki pomeni „če“, in je torej v nasprotju s predvidenim pomenom.
It is therefore necessary to correct the Slovak language version of the Regulation.
Zato je treba slovaško jezikovno različico Uredbe popraviti.
All other language versions are not affected.
To ne zadeva nobene druge jezikovne različice.
Implementing Regulation (EU) 2015/2403 should therefore be corrected accordingly.
Izvedbeno uredbo (EU) 2015/2403 bi bilo zato treba ustrezno popraviti.
The measures provided for in this Regulation are in accordance with the opinion of the Committee established by Directive 91/477/EEC,
Ukrepi iz te uredbe so v skladu z mnenjem odbora, ustanovljenega z Direktivo 91/477/EGS –
(Does not concern the English language)
(ne zadeva slovenskega jezika)
OJ L 256, 13.9.1991, p. 51.
UL L 256, 13.9.1991, str. 51.
Commission Implementing Regulation (EU) 2015/2403 of 15 December 2015 establishing common guidelines on deactivation standards and techniques for ensuring that deactivated firearms are rendered irreversibly inoperable (OJ L 333, 19.12.2015, p. 62).
Izvedbena uredba Komisije (EU) 2015/2403 z dne 15. decembra 2015 o določitvi skupnih smernic o standardih in tehnikah za onesposobitev, ki zagotavljajo nepreklicno neuporabnost onesposobljenega strelnega orožja (UL L 333, 19.12.2015, str. 62).
Commission Implementing Regulation (EU) 2017/1205
Izvedbena uredba Komisije (EU) 2017/1205
laying down the allocation coefficient to be applied to the quantities covered by the applications for import licences lodged from 23 June 2017 to 30 June 2017 under the tariff quotas opened by Implementing Regulation (EU) 2015/2081 for certain cereals originating in Ukraine
o določitvi koeficienta dodelitve, ki se uporabi za količine v zahtevkih za izdajo uvoznih dovoljenj, vloženih od 23. junija 2017 do 30. junija 2017 v okviru tarifnih kvot, odprtih z Izvedbeno uredbo (EU) 2015/2081 za nekatera žita s poreklom iz Ukrajine
Article 1(1) of Implementing Regulation (EU) 2015/2081 set, for the period from 1 January 2017 to 31 December 2017 the quantity of the quota with order number 09.4307 at 270000 tonnes.
Člen 1(1) Izvedbene uredbe (EU) 2015/2081 določa za obdobje od 1. januarja 2017 do 31. decembra 2017 količino kvote z zaporedno številko 09.4307 na 270000 ton.
The quantities covered by the applications for import licences lodged from 23 June 2017 from 13.00 to 30 June 2017 at 13.00 (Brussels time) exceed those available for the quota with order number 09.4307.
Količine v zahtevkih za izdajo uvoznih dovoljenj, vloženih od 23. junija 2017 od 13. ure po bruseljskem času do 30. junija 2017 do 13. ure po bruseljskem času za kvoto z zaporedno številko 09.4307, presegajo razpoložljive količine.